Literature DB >> 19825953

Estrogen receptor-negative breast cancer: new insights into subclassification and targeting.

Jean J Zhao1, Daniel P Silver.   

Abstract

Classification schemes for disease states can help identify distinctions with useful implications for therapy and prognosis. Speers and colleagues provide a new subclassification scheme for estrogen receptor-negative breast cancer based upon kinome-wide gene expression profiling with interesting findings that are potentially relevant for both treatment and clinical outcome.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19825953      PMCID： PMC2904516          DOI： 10.1158/1078-0432.CCR-09-2010

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Authors:  Roman Rouzier; Charles M Perou; W Fraser Symmans; Nuhad Ibrahim; Massimo Cristofanilli; Keith Anderson; Kenneth R Hess; James Stec; Mark Ayers; Peter Wagner; Paolo Morandi; Chang Fan; Islam Rabiul; Jeffrey S Ross; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Authors:  Lisa A Carey; E Claire Dees; Lynda Sawyer; Lisa Gatti; Dominic T Moore; Frances Collichio; David W Ollila; Carolyn I Sartor; Mark L Graham; Charles M Perou
Journal:  Clin Cancer Res       Date:  2007-04-15       Impact factor: 12.531

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 7.  Trastuzumab in breast cancer.

Authors:  Leisha A Emens; Nancy E Davidson
Journal:  Oncology (Williston Park)       Date:  2004-08       Impact factor: 2.990

8.  Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.

Authors:  Lao H Saal; Sofia K Gruvberger-Saal; Camilla Persson; Kristina Lövgren; Mervi Jumppanen; Johan Staaf; Göran Jönsson; Maira M Pires; Matthew Maurer; Karolina Holm; Susan Koujak; Shivakumar Subramaniyam; Johan Vallon-Christersson; Håkan Olsson; Tao Su; Lorenzo Memeo; Thomas Ludwig; Stephen P Ethier; Morten Krogh; Matthias Szabolcs; Vundavalli V V S Murty; Jorma Isola; Hanina Hibshoosh; Ramon Parsons; Ake Borg
Journal:  Nat Genet       Date:  2007-12-09       Impact factor: 38.330

9.  Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.

Authors:  Shidong Jia; Zhenning Liu; Sen Zhang; Pixu Liu; Lei Zhang; Sang Hyun Lee; Jing Zhang; Sabina Signoretti; Massimo Loda; Thomas M Roberts; Jean J Zhao
Journal:  Nature       Date:  2008-06-25       Impact factor: 49.962

10.  PTEN-deficient cancers depend on PIK3CB.

Authors:  Susan Wee; Dmitri Wiederschain; Sauveur-Michel Maira; Alice Loo; Christine Miller; Rosalie deBeaumont; Frank Stegmeier; Yung-Mae Yao; Christoph Lengauer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-28       Impact factor: 11.205
View more
  2 in total

Review 1.  Targeting autophagy in breast cancer.

Authors:  Paola Maycotte; Andrew Thorburn
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.

Authors:  Ali Naderi; Kee Ming Chia; Ji Liu
Journal:  Breast Cancer Res       Date:  2011-04-01       Impact factor: 6.466
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.